HTL Biotechnology Acquires Modern Meadow’s Recombinant Human Collagen Platform to Expand Its Leadership in Pharmaceutical-Grade Biopolymers
Modern Meadow
Bio-leather Manufacturer
HTL Biotechnology
Pharmaceutical-Grade Hyaluronic Acid Developer and Manufacturer
Recently, HTL Biotechnology (Chinese: Haiya Touning) announced that it has successfully acquiredThe Beauty and Biomedical Division of Modern Meadow (Nutley, New Jersey, USA), further solidifying its global leading position in the production and development of pharmaceutical-grade biopolymers. The most advanced product from Modern Meadow's recombinant human collagen platform, which was acquired in this transaction, isRecombinant Human Type III Collagen (rhCOL3)。
▷Modern MeadowIt is a biotechnology company located in New York that has been committed to the development of bio-leather. The company received Series A and Series B financing in 2014 and 2016, respectively, with investors includingHorizons Ventures, the venture capital firm under Li Ka-shing(Horizons Ventures), as of now, the companyThe cumulative total of financing has reached 184 million US dollars ((Approximately RMB 1.328 billion).
▷HTL Biotechnology's acquisition includes Modern Meadow's recombinant protein platform, whereinThe most advanced product is human recombinant type III collagen (rhCOL3).rhCOL3, developed by the United States and produced in Europe, has already attracted significant interest from numerous participants in the cosmetics and beauty industry. The recombinant human collagen market is still in its infancy but is experiencing high demand and will soon surpass the billion-dollar mark.
▷HTL Biotechnology will go through this platformOffer a Diversified and Distinctive Product Range, including pharmaceutical-grade hyaluronic acid, polynucleotides, and products under development such as heparin or botulinum toxin as neuromodulators. In addition, through this acquisition, HTL Biotechnology has gained an exclusive recombinant human collagen platform.
▷HTL Biotechnology Hopes to Drive Its Growth in China Through This AcquisitionCosmetic Medicine, Rheumatology, and OphthalmologyInnovative development in traditional fields, and exploration in new therapeutic areas. The synergy between HTL's GMP biofermentation expertise and this new recombinant protein platform will drive disruptive innovation.Through the comprehensive utilization of biopolymers, HTL will accelerate the enhancement of its R&D and innovation capabilities.
▷François Fournier, CEO of HTL"I am very excited about the commercialization of this new type of pure vegan biopolymer, the diversification of our business, and the prospects for further innovation that this acquisition brings us. HTL Biotechnology has thus become a pioneer in the human recombinant collagen market, just as the company was a pioneer in the bio-production of hyaluronic acid 30 years ago. The far-reaching impact of our biopolymer product series is unique, and we will be very proud to provide better services to our customers. On behalf of HTL Biotechnology, I am delighted to welcome Modern Meadow's beauty and biomedical teams."
▷Chairman of HTL, Paul Navarre"This strategic acquisition marks that HTL Biotechnology will accelerate its development, international expansion, and product portfolio diversification, and will consolidate its leading position in the biopolymer field by providing a large number of innovative products."
About HTL Biotechnology
▷HTL Biotechnology (Chinese: Haiya Tounin) is a French biotechnology company inPharmaceutical-Grade BiopolymerModern Meadow, Inc. is a world leader in the development and bioproduction field, with its biopolymers used by healthcare companies forDevelopment of Ophthalmology, Dermatology, Medical Aesthetics and RheumatologyTherapies in multiple major treatment areas.
▷For more than 30 years, HTL Biotechnology has been a driving force of innovation in the field, collaborating with research entities and biotech companies to meet future medical needs (regenerative medicine, drug delivery, etc.).
▷HTLBiotechnologyIs a rapidly developing international company,Nearly 80% of the products are exported to more than 30 countries.To meet the growing global demand for biopolymers, HTL Biotechnology has also established subsidiaries in Singapore and the United States, and set up a neuromodulator production unit (HTL BMI - Massachusetts).
